This site is intended for US healthcare professionals only.
PEDIATRIC PATIENTS: The pharmacokinetics, safety, and efficacy of maraviroc in patients younger than 2 years have not been established. Therefore, SELZENTRY is not recommended in this patient population. Additionally, there are insufficient data to make dosing recommendations for use of SELZENTRY in pediatric patients concomitantly receiving noninteracting medications and weighing less than 30 kg or in pediatric patients concomitantly receiving potent CYP3A inducers without a potent CYP3A inhibitor.
Please see full Prescribing Information, including Boxed Warning and Medication Guide, for SELZENTRY.